Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
Executive Summary
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
You may also be interested in...
US FDA’s Woodcock Outlines Plans For Quicker Inspection Workflow Platform, Expected Next Year
Inspection ordering and case management software launched with food program revamp will bring real time coordination between the US FDA’s inspectorate and all its centers, enabling quicker, surer deployment and better development of cases against sites found to have poor manufacturing practices.
Will Califf’s Attention To Foods Come At Expense Of US FDA’s Drugs Program?
FDA Commissioner Robert Califf says the medical product programs have received a lot of attention and now it’s the food program’s turn.
The Quality Lowdown: The Effort Required To Stem Substandard, Illegitimate, Unapproved Drugs
As stakeholders in the US pharmaceutical distribution chain prepare to coordinate against suspect drugs, the world’s leading inspectorates collaborate on good distribution practices.